目的 探讨 PD-1 单抗联合及呋喹替尼单药对晚期转移性结直肠癌的效果、安全性及预后影响因素。方法 纳入自 2018 年 6 月至 2021 年 12 月在医院接受呋喹替尼联合 PD-1 抑制剂治疗的 31 例、呋 喹替尼单药治疗的 42 例及四线化疗 35 例患者为研究对象，回顾性地分析患者的疗效、生存期及主要不良反应，探讨无进展生存期（PFS）及总生存期（OS）的危险因素。结果 联合用药组与化疗组及单药组 PFS 比较存在差异，与化疗组比较OS 差异显著。分化程度及治疗方案是影响联合用药组与化疗组患者PFS 的 独立危险因素，治疗方案是影响患者OS 的独立危险因素。分化程度是影响联合用药与单药组患者PFS 的 独立危险因素。呋喹替尼单药或联合 PD-1 较传统化疗多项不良反应发生率降低，而高血压发生率升高。 结论 呋喹替尼联合 PD-1 单抗后线治疗晚期 CRC 患者具有潜在的疗效和可控的安全性，分化程度可能是影响患者PFS 的独立危险因素。 

Objective Explored the efficacy， safety and prognostic factors of furoquinitinib alone and in combination with PD-1 monoclonal antibody in advanced metastatic colorectal cancer that failed to be treated with standard regimens. Methods From June 2018 to December 2021，31 patients who were treated with Furoquintinib combined with PD-1 inhibitor，42 patients who were treated with Furoquintinib alone and 35 patients who were treated with fourth-line chemotherapy were included as the research objects. The efficacy，survival time and major adverse reactions of patients were analyzed retrospectively，and the risk factors of progression-free survival （PFS） and overall survival （OS） were discussed. Results Significant differences in PFS were observed in the PD-1 inhibitor combined with furoquinitinib group compared with the chemotherapy group or the monotherapy group， and significant differences in OS compared with the chemotherapy group. The degree of differentiation and treatment regimen were independent risk factors affecting PFS in patients in the furoquinitinib combining PD-1 inhibitor versus chemotherapy group， while the treatment regimen was an independent risk factor affecting patients' OS. The degree of differentiation was an independent risk factor for PFS in patients in the PD-1 monoclonal antibody combination versus single agent group. The incidence of several adverse reactions was reduced with furoquinitinib alone or in combination with PD-1 inhibitor compared with conventional chemotherapy， while the incidence of hypertension was increased. Conclusions Furoquinitinib in combination with PD-1 monoclonal antibody has potential efficacy and a manageable safety profile in the backline treatment of patients with advanced mCRC. The degree of differentiation may be an independent risk factor for PFS in patients.